194 related articles for article (PubMed ID: 8625321)
1. Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression.
Tan RS; Taniguchi T; Harada H
Cancer Res; 1996 May; 56(10):2417-21. PubMed ID: 8625321
[TBL] [Abstract][Full Text] [Related]
2. IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo.
Kröger A; Dallügge A; Kirchhoff S; Hauser H
Oncogene; 2003 Feb; 22(7):1045-56. PubMed ID: 12592391
[TBL] [Abstract][Full Text] [Related]
3. Transcription factor IRF-2 exerts its oncogenic phenotype through the DNA binding/transcription repression domain.
Nguyen H; Mustafa A; Hiscott J; Lin R
Oncogene; 1995 Aug; 11(3):537-44. PubMed ID: 7630638
[TBL] [Abstract][Full Text] [Related]
4. Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis.
Kirchhoff S; Hauser H
Oncogene; 1999 Jun; 18(25):3725-36. PubMed ID: 10391680
[TBL] [Abstract][Full Text] [Related]
5. Deregulated expression of interferon regulatory factor-1 in oncogene-transformed mouse fibroblasts.
Contente S; Attard FA; Yeh TJ; Buchhagen DL; Friedman RM
J Interferon Cytokine Res; 2003 Nov; 23(11):639-47. PubMed ID: 14651778
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma regulation of the human mimecan promoter.
Tasheva ES; Conrad GW
Mol Vis; 2003 Jun; 9():277-87. PubMed ID: 12835654
[TBL] [Abstract][Full Text] [Related]
7. Identification of the secretory leukocyte protease inhibitor (SLPI) as a target of IRF-1 regulation.
Nguyen H; Teskey L; Lin R; Hiscott J
Oncogene; 1999 Sep; 18(39):5455-63. PubMed ID: 10498899
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic inhibition of lysyl oxidase transcription after transformation by ras oncogene.
Contente S; Kenyon K; Sriraman P; Subramanyan S; Friedman RM
Mol Cell Biochem; 1999 Apr; 194(1-2):79-91. PubMed ID: 10391127
[TBL] [Abstract][Full Text] [Related]
9. Comparative functional study of the lysyl oxidase promoter in fibroblasts, Ras-transformed fibroblasts, myofibroblasts and smooth muscle cells.
Reynaud C; Gleyzal C; Jourdan-Le Saux C; Sommer P
Cell Mol Biol (Noisy-le-grand); 1999 Dec; 45(8):1237-47. PubMed ID: 10643973
[TBL] [Abstract][Full Text] [Related]
10. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development.
Matsuyama T; Kimura T; Kitagawa M; Pfeffer K; Kawakami T; Watanabe N; Kündig TM; Amakawa R; Kishihara K; Wakeham A
Cell; 1993 Oct; 75(1):83-97. PubMed ID: 8402903
[TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor-alpha and interferon-gamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors.
Lee AH; Hong JH; Seo YS
Biochem J; 2000 Aug; 350 Pt 1(Pt 1):131-8. PubMed ID: 10926836
[TBL] [Abstract][Full Text] [Related]
12. The role of the interferon regulatory factors, IRF-1 and IRF-2, in LPS-induced cyclooxygenase-2 (COX-2) expression in vivo and in vitro.
Zhang S; Thomas K; Blanco JC; Salkowski CA; Vogel SN
J Endotoxin Res; 2002; 8(5):379-88. PubMed ID: 12537697
[TBL] [Abstract][Full Text] [Related]
13. Negative modulation of alpha1(I) procollagen gene expression in human skin fibroblasts: transcriptional inhibition by interferon-gamma.
Yuan W; Yufit T; Li L; Mori Y; Chen SJ; Varga J
J Cell Physiol; 1999 Apr; 179(1):97-108. PubMed ID: 10082137
[TBL] [Abstract][Full Text] [Related]
14. IFN regulatory factor-1 gene transfer into an aggressive, nonimmunogenic sarcoma suppresses the malignant phenotype and enhances immunogenicity in syngeneic mice.
Yim JH; Wu SJ; Casey MJ; Norton JA; Doherty GM
J Immunol; 1997 Feb; 158(3):1284-92. PubMed ID: 9013971
[TBL] [Abstract][Full Text] [Related]
15. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells.
Su ZZ; Austin VN; Zimmer SG; Fisher PB
Oncogene; 1993 May; 8(5):1211-9. PubMed ID: 8479744
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of lysyl oxidase in spontaneous revertants of H-ras-transformed rat fibroblasts.
Hajnal A; Klemenz R; Schäfer R
Cancer Res; 1993 Oct; 53(19):4670-5. PubMed ID: 7691400
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppression by IFN regulatory factor-1 is mediated by transcriptional down-regulation of cyclin D1.
Kröger A; Stirnweiss A; Pulverer JE; Klages K; Grashoff M; Reimann J; Hauser H
Cancer Res; 2007 Apr; 67(7):2972-81. PubMed ID: 17409403
[TBL] [Abstract][Full Text] [Related]
18. Expression of the protein kinase PKR in modulated by IRF-1 and is reduced in 5q- associated leukemias.
Beretta L; Gabbay M; Berger R; Hanash SM; Sonenberg N
Oncogene; 1996 Apr; 12(7):1593-6. PubMed ID: 8622878
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity.
Kondo T; Minamino N; Nagamura-Inoue T; Matsumoto M; Taniguchi T; Tanaka N
Oncogene; 1997 Sep; 15(11):1275-81. PubMed ID: 9315094
[TBL] [Abstract][Full Text] [Related]
20. Activation of a cell-cycle-regulated histone gene by the oncogenic transcription factor IRF-2.
Vaughan PS; Aziz F; van Wijnen AJ; Wu S; Harada H; Taniguchi T; Soprano KJ; Stein JL; Stein GS
Nature; 1995 Sep; 377(6547):362-5. PubMed ID: 7566094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
